Multiple Myeloma

Multiple myeloma is the second most prevalent hematological malignancy with over 55000 new cases diagnosed each year. This exciting new text edited by lauded authorities on the topic stands as the only available reference to assemble review and synthesizes the latest studies on translational therapies and clearly explains the impact of molecular pathogenesis biology and prognostic factors on the diagnosis prognosis and individualization of treatment and the development of novel therapeutic options for patients with myeloma.